Exploring the interplay between adipokine-mediated celastrol target genes and T cells in diabetic nephropathy: a

Xiaojuan Wang1,2, Mohamad Hafizi Abu Bakar3, Mohd Asyraf Kassim2

  • 1Department of Pharmacy, Taishan Vocational College of Nursing, Tai'an, Shandong, 271099, China.

PubMed
Abstract

Insights

Celastrol targets key genes like FGF9, MAGI2, and THBS2 to modulate diabetic nephropathy (DN) by influencing adipokine-immune crosstalk and lipid metabolism. This offers potential for new biomarkers and therapies for DN.

Area of Science:

  • Endocrinology
  • Nephrology
  • Immunology

Background:

  • Diabetic nephropathy (DN) involves dysregulated adipokines affecting inflammation and metabolism.
  • The exact mechanisms linking adipokines, immune cells, and metabolic changes in DN are not fully understood.
  • Celastrol shows potential in mitigating renal damage, but its specific role in DN's adipokine-immune interactions needs clarification.

Purpose of the Study:

  • To elucidate the interplay between adipokine-mediated target genes in diabetic nephropathy (DN).
  • To investigate how celastrol modulates these interactions in DN.
  • To identify potential therapeutic targets and biomarkers for DN.

Main Methods:

  • Analysis of gene expression profiles from DN patient datasets (GSE30122, GSE30528).
  • Utilized Gene Set Variation Analysis (GSVA) for lipid metabolism pathways.
  • Employed Mendelian randomization (MR) and Pearson correlation to assess gene-adipokine associations and immune cell infiltration.

Main Results:

  • Identified 70 differentially expressed genes (DEGs) in DN.
  • Found altered adipocyte differentiation pathways and significant associations of adiponectin, leptin, and resistin with DN.
  • Highlighted FGF9, MAGI2, and THBS2 as key genes linked to DN risk and T cell infiltration, with 22 celastrol target genes identified among them.

Conclusions:

  • Celastrol influences DN progression via adipokine-immune crosstalk.
  • FGF9, MAGI2, and THBS2 are identified as crucial regulatory genes in DN.
  • These findings suggest novel avenues for DN biomarker discovery and therapeutic development.

Related Concept Videos

Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
17
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
28
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
32